Is ResMed Inc. (CHESS) (ASX:RMD) under threat from this high growth innovator?

This New York Stock Exchange listed upstart is innovating in an industry dominated by ResMed Inc. (CHESS) (ASX: RMD)

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

"Many people have sleep apnea, but may not even know it. In fact, sleep apnea affects more than 3 in 10 men and nearly 1 in 5 women, so it's more common than you might think".

That's a direct quote from the ResMed Inc. (CHESS) (ASX: RMD) website and in my view, one of the key reasons that make Resmed an attractive investment

Like CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH), Resmed has a large total addressable market and has been capturing more of that market.

Resmed's revenues grow at double-digit rates and in the last financial year, it made US$2.3 billion in revenue. That is a lot of money for a company that still has a large market to capture.

Its no wonder then that this lucrative market has attracted competition with the latest being the New York Stock Exchange (NYSE) listed Inspire Medical Systems Inc.

Unlike Resmed's CPAP devices, Inspire's therapy devices are mainly inside the body and do not require the patient to wear a mask. The images below provide a visual comparison between a Resmed mask and Inspire's therapy.

Source: Resmed website
Source: Inspire website

I have never used a CPAP device before, but I would imagine that the mask might be more uncomfortable to use.

So is Resmed under threat from this disruptive innovator? Here are some reasons why I think investors should take the threat from Inspire seriously:

  • Whilst Inspire only started trading on the NYSE this year and has a market cap of less than US$1 billion, it is a spin-off from Medtronic PLC, another NYSE listed company which has a market cap of US$125 billion. That's the kind of backing you want to see in a small company, from a company that has a lot of relevant IP and deep pockets.
  • Inspire has a very high sales growth rate of over 80% which is very impressive, even though it's coming from a lower base compared to Resmed.
  • Inspire has higher gross margins (roughly 80% compared to Resmed's 58%) although it's not yet profitable.

Foolish Takeaway

For now, I think there is no immediate threat to Resmed's bottom line but investors will need to keep an eye on Resmed's R&D investments and how their products compare to new upstarts such as Inspire.

Motley Fool contributor Kevin Gandiya has no position in any of the stocks mentioned. You can find Kevin on Twitter @KevinGandiya. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Regis Healthcare expects FY26 EBITDA to hit top end of guidance

Regis Healthcare expects top-end FY26 earnings as strong occupancy, RAD inflows, and efficiency gains set a positive outlook.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Healthcare Shares

This ASX healthcare stock could be set to rise 50%

This small cap could be one to watch.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

Up 60%: Why this exciting ASX stock could keep rising

This speculative stock could still have significant upside according to Bell Potter.

Read more »